Supplementary Tables S1-S7 from Depleting MET-Expressing Tumor Cells by ADCC Provides a Therapeutic Advantage over Inhibiting HGF/MET Signaling

Supplementary Tables S1-S7. Binding of WT52, WT52-E and WT52-D to human and mouse Fc gamma receptors (S1); ADCC activity of engineered antibodies (S2); In vitro characterization of the germlined G52 antibody (S3); Binding of G52 and ARGX-111 to human, mouse and simian Fc receptors (S4); ARGX-111 displays dose-dependent binding to MET-expressing human cell lines (S5); ARGX-111 promotes ADCC of MET-expressing human tumor cell lines (S6); Mammary carcinoma stem cells express MET (S7).